Filing Details
- Accession Number:
- 0001415889-24-016672
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-06-13 16:15:42
- Reporting Period:
- 2024-06-11
- Accepted Time:
- 2024-06-13 16:15:42
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1159036 | Halozyme Therapeutics Inc. | HALO | Biological Products, (No Disgnostic Substances) (2836) | 880488686 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1543792 | L. Matthew Posard | C/O Halozyme Therapeutics, Inc. 12390 El Camino Real San Diego CA 92130 | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2024-06-11 | 10,000 | $50.01 | 109,755 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-06-12 | 10,000 | $50.62 | 99,755 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Footnotes
- Represents a weighted average sales price per share. The shares were sold at prices ranging from $50.00 to $50.21. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- Includes 20,722 stock units that are subject to a written deferral election under the Issuer's Directors Deferred Equity Compensation Plan pursuant to which shares of common stock are released to the reporting person upon completion of service as a director.
- Represents a weighted average sales price per share. The shares were sold at prices ranging from $50.50 to $50.935. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Billionaire Hedge Funds
